查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1692179

α發射體市場 - 全球產業規模、佔有率、趨勢、機會和預測，按放射性核種類型（砹、鐳、錒、鉛、鉍、其他）、按醫療應用、按地區和競爭細分，2020-2030 年預測

Alpha Emitter Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Type of Radionuclide (Astatine, Radium, Actinium, Lead, Bismuth, Other), By Medical Application, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球α發射體市場價值為 4.661 億美元，預計在預測期內將實現強勁成長，到 2030 年的複合年成長率為 9.80%。全球α發射體市場是核醫和放射治療領域內的專業部門。它圍繞著發射阿爾法放射性核種的生產、分佈和應用展開，阿爾法放射性核種是發射阿爾法粒子的放射性同位素。這是由於疾病盛行率不斷上升、癌症病例不斷增加、人口老化不斷加劇等原因造成的。例如，國際癌症研究機構 (IARC) 預測，到 2040 年，全球癌症負擔將上升至 2,750 萬新病例和 1,630 萬癌症相關死亡病例，這主要是由於人口成長和老化造成的。此外，2022 年 8 月《輻射》雜誌上的一篇文章介紹了日本近畿大學一位科學家的研究，探索了鐳-223 療法對轉移性去勢抵抗性前列腺癌的最佳應用。研究表明，早期使用 Ra-223 可顯著提高整體存活率 (OS)，凸顯了在新型荷爾蒙或抗癌治療之前使用 Ra-223 的潛在優勢。阿爾法發射體因其獨特的特性在醫療、工業和能源領域佔據了重要地位，市場正在經歷顯著的成長和創新。由於釋放了由兩個質子和兩個中子組成的阿爾法粒子。這些粒子帶電性很強，在組織中的傳播範圍很短，因此可有效局部治療。阿爾法輻射效力強大，能夠精確地損害和摧毀癌細胞，同時保護附近的健康組織。

市場概況
預測期 2026-2030
2024 年市場規模 4.661億美元
2030 年市場規模 8.1037億美元
2025-2030 年複合年成長率 9.80％
成長最快的領域 卵巢癌
最大的市場 北美洲

主要市場促進因素

核子醫學需求不斷成長

主要市場挑戰

監管障礙

主要市場趨勢

標靶阿爾法粒子治療的進展：

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球α發射體市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依放射性核種類型（砹（At-211）、鐳（Ra-223）、錒（Ac-225）、鉛（Pb-212）、鉍（Bi-212）、其他）
    • 依醫療應用（前列腺癌、骨轉移、卵巢癌、胰臟癌、內分泌腫瘤、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美α發射體市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第7章：歐洲α發射體市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區α發射體市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲α發射體市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲α發射體市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式

第 11 章：2 個挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 13 章：全球α發射體市場：SWOT 分析

第 14 章：競爭格局

  • Actinium Pharmaceutical Inc.
  • Alpha Tau Medical Ltd
  • Bayer AG
  • Fusion Pharmaceuticals
  • IBA Radiopharma Solutions
  • RadioMedix Inc.
  • Telix Pharmaceuticals Ltd
  • Novartis International AG
  • Isotopen Technologien Munchen AG (ITM)
  • NorthStar Medical Radioisotopes

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 17417

Global Alpha Emitter Market Was valued at USD 466.10 million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 9.80% through 2030. The Global Alpha Emitter Market is a specialized sector within the broader field of nuclear medicine and radiation therapy. It revolves around the production, distribution, and application of alpha-emitting radionuclides, which are radioactive isotopes emitting alpha particles. This is ascribed due to the growing disease prevalence, growing cancer cases, rising aging population, etc. For instance, the International Agency for Research on Cancer (IARC) projects that by 2040, the global cancer burden will rise to 27.5 million new cases and 16.3 million cancer-related deaths, largely due to population growth and aging. Additionally, an August 2022 article in the Radiation journal featured research by a Kindai University scientist in Japan exploring the optimal use of Radium-223 therapy for Metastatic Castration-Resistant Prostate Cancer. The study indicated that early administration of Ra-223 significantly improved overall survival (OS), highlighting potential advantages of using Ra-223 before novel hormonal or anticancer treatments. Alpha emitters have gained prominence in medical, industrial, and energy sectors due to their unique characteristics, and the market is experiencing notable growth and innovation. Due to the release of alpha particles, which consist of two protons and two neutrons. These particles are highly charged and have a short range in tissue, making them effective for localized therapy. Alpha radiation is potent, capable of damaging and destroying cancer cells with precision while sparing nearby healthy tissue.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 466.10 Million
Market Size 2030USD 810.37 Million
CAGR 2025-20309.80%
Fastest Growing SegmentOvarian Cancer
Largest MarketNorth America

Key Market Drivers

Growing Demand for Nuclear Medicine

One of the primary drivers of the Global Alpha Emitter Market is the increasing demand for nuclear medicine. Advances in medical science have revealed the efficacy of alpha emitters in targeted cancer therapy. Alpha particles are highly effective at killing cancer cells, making them a vital component of radiopharmaceuticals used in cancer treatment. The shift towards precision medicine is another key reason for the growing demand. Medical professionals are increasingly tailoring treatments to individual patients, and alpha emitters offer a precise way to target cancerous cells while minimizing damage to healthy tissue. The global rise in cancer cases is a significant driver. As cancer incidence continues to increase, the demand for effective treatment options also grows. Alpha emitters provide a promising solution for certain types of cancers that are challenging to treat through conventional methods. Ongoing clinical trials and research efforts are further fueling demand. Pharmaceutical companies and research institutions are investing heavily in the development of new alpha-emitting radiopharmaceuticals, expanding the range of treatable conditions. Increasing patient awareness and advocacy groups' efforts have contributed to the demand for nuclear medicine. Patients and their families are seeking out cutting-edge treatments, and alpha emitter-based therapies are becoming more accessible and sought after.

Key Market Challenges

Regulatory Hurdles

Regulatory hurdles, such as stringent licensing and safety regulations, can significantly impede the growth of the Global Alpha Emitter Market. Governments and regulatory bodies closely monitor the use and transport of radioactive materials, including alpha emitters, due to safety concerns. This leads to lengthy approval processes and strict compliance requirements. The highly radioactive nature of alpha emitters necessitates rigorous oversight to prevent accidents and ensure public safety. However, the complexity and stringency of regulatory processes can slow down the development and commercialization of alpha-emitting products. Companies may face delays and increased costs in navigating the regulatory landscape, hindering market growth.

Key Market Trends

Advancements in Targeted Alpha-Particle Therapy:

A significant trend in the Global Alpha Emitter Market is the continuous advancements in targeted alpha-particle therapy. This therapy involves the use of alpha-emitting radiopharmaceuticals to precisely target and destroy cancer cells while sparing healthy tissue. Recent research and development efforts have led to the creation of novel alpha-emitting compounds that are more effective and have reduced side effects. This trend is driven by the increasing focus on personalized medicine in oncology. Healthcare providers and pharmaceutical companies are investing in research to develop alpha emitters that can be tailored to a patient's specific cancer type and genetic profile. As a result, targeted alpha-particle therapy is gaining prominence as a promising and minimally invasive treatment option for various cancers, including prostate, bone, and pancreatic cancer.

Key Market Players

  • Actinium Pharmaceutical Inc.
  • Alpha Tau Medical Ltd
  • Bayer AG
  • Fusion Pharmaceuticals
  • IBA Radiopharma Solutions
  • RadioMedix Inc.
  • Telix Pharmaceuticals Ltd
  • Novartis International AG
  • Isotopen Technologien Munchen AG(ITM)
  • NorthStar Medical Radioisotopes

Report Scope:

In this report, the Global Alpha Emitter Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alpha Emitter Market, By Type of Radionuclide:

  • Astatine (At-211)
  • Radium (Ra-223)
  • Actinium (Ac-225)
  • Lead (Pb-212)
  • Bismuth (Bi-212)
  • Other

Alpha Emitter Market, By Medical Application:

  • Prostate Cancer
  • Bone Metastasis
  • Ovarian Cancer
  • Pancreatic Cancer
  • Endocrine Tumors
  • Other

Alpha Emitter Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alpha Emitter Market.

Available Customizations:

Global Alpha Emitter market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alpha Emitter Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type of Radionuclide (Astatine (At-211), Radium (Ra-223), Actinium (Ac-225), Lead (Pb-212), Bismuth (Bi-212), Other)
    • 5.2.2. By Medical Application (Prostate Cancer, Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Alpha Emitter Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Radionuclide
    • 6.2.2. By Medical Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Alpha Emitter Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type of Radionuclide
        • 6.3.1.2.2. By Medical Application
    • 6.3.2. Canada Alpha Emitter Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type of Radionuclide
        • 6.3.2.2.2. By Medical Application
    • 6.3.3. Mexico Alpha Emitter Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type of Radionuclide
        • 6.3.3.2.2. By Medical Application

7. Europe Alpha Emitter Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Radionuclide
    • 7.2.2. By Medical Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Alpha Emitter Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type of Radionuclide
        • 7.3.1.2.2. By Medical Application
    • 7.3.2. United Kingdom Alpha Emitter Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type of Radionuclide
        • 7.3.2.2.2. By Medical Application
    • 7.3.3. Italy Alpha Emitter Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type of Radionuclide
        • 7.3.3.2.2. By Medical Application
    • 7.3.4. France Alpha Emitter Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type of Radionuclide
        • 7.3.4.2.2. By Medical Application
    • 7.3.5. Spain Alpha Emitter Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type of Radionuclide
        • 7.3.5.2.2. By Medical Application

8. Asia-Pacific Alpha Emitter Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Radionuclide
    • 8.2.2. By Medical Application
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Alpha Emitter Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type of Radionuclide
        • 8.3.1.2.2. By Medical Application
    • 8.3.2. India Alpha Emitter Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type of Radionuclide
        • 8.3.2.2.2. By Medical Application
    • 8.3.3. Japan Alpha Emitter Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type of Radionuclide
        • 8.3.3.2.2. By Medical Application
    • 8.3.4. South Korea Alpha Emitter Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type of Radionuclide
        • 8.3.4.2.2. By Medical Application
    • 8.3.5. Australia Alpha Emitter Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type of Radionuclide
        • 8.3.5.2.2. By Medical Application

9. South America Alpha Emitter Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Radionuclide
    • 9.2.2. By Medical Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Alpha Emitter Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type of Radionuclide
        • 9.3.1.2.2. By Medical Application
    • 9.3.2. Argentina Alpha Emitter Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type of Radionuclide
        • 9.3.2.2.2. By Medical Application
    • 9.3.3. Colombia Alpha Emitter Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type of Radionuclide
        • 9.3.3.2.2. By Medical Application

10. Middle East and Africa Alpha Emitter Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Radionuclide
    • 10.2.2. By Medical Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Alpha Emitter Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type of Radionuclide
        • 10.3.1.2.2. By Medical Application
    • 10.3.2. Saudi Arabia Alpha Emitter Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type of Radionuclide
        • 10.3.2.2.2. By Medical Application
    • 10.3.3. UAE Alpha Emitter Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type of Radionuclide
        • 10.3.3.2.2. By Medical Application

11. Market Dynamics

  • 11.1. Drivers

11.2 Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Alpha Emitter Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Actinium Pharmaceutical Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Medical Application Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Key Personnel
    • 14.1.5. SWOT Analysis
  • 14.2. Alpha Tau Medical Ltd
  • 14.3. Bayer AG
  • 14.4. Fusion Pharmaceuticals
  • 14.5. IBA Radiopharma Solutions
  • 14.6. RadioMedix Inc.
  • 14.7. Telix Pharmaceuticals Ltd
  • 14.8. Novartis International AG
  • 14.9. Isotopen Technologien Munchen AG (ITM)
  • 14.10. NorthStar Medical Radioisotopes

15. Strategic Recommendations

16. About Us & Disclaimer